Literature DB >> 22438101

Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.

Min-Bin Chen1, Xiao-Yang Wu, Guo-Qing Tao, Chao-Ying Liu, Jian Chen, Li-Qiang Wang, Pei-Hua Lu.   

Abstract

Our study shows that coadministration of curcumin and an orally bioactive alkylphospholipid perifosine results in a significant increase in colorectal cancer cell apoptosis and a marked inhibition of cell growth both in vitro and in vivo. This novel combinatorial regimen leads to changes of multiple cell signaling pathways including inactivation of Akt and nuclear factor-κB as well as activation of c-Jun N-terminal kinases and endoplasmic reticulum stress. Further, perifosine and curcumin synergistically increase intracellular level of reactive oxygen species and ceramide, and downregulate the expression of cyclin D1 and Bcl-2 in colorectal cancer cells. These changes at molecular level together account for the cancer cell apoptosis and growth inhibition. We conclude that perifosine sensitizes colorectal cancer cells to curcumin by modulating multiple signaling pathways. Adding perifosine with curcumin may represent an effective therapy regimen against colorectal cancers, and possible other aggressive tumors.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438101     DOI: 10.1002/ijc.27548

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Modulation of apoptosis-related cell signalling pathways by curcumin as a strategy to inhibit tumor progression.

Authors:  Jin Chen; Feng-Ling Wang; Wei-Dong Chen
Journal:  Mol Biol Rep       Date:  2014-03-07       Impact factor: 2.316

2.  Curcumin induces apoptosis in human leukemic cell lines through an IFIT2-dependent pathway.

Authors:  Yonglu Zhang; Yunyuan Kong; Shuyuan Liu; Lingbing Zeng; Lagen Wan; Zhanglin Zhang
Journal:  Cancer Biol Ther       Date:  2017-01-10       Impact factor: 4.742

3.  Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma.

Authors:  Marion Le Grand; Kathleen Kimpton; Christine C Gana; Emanuele Valli; Jamie I Fletcher; Maria Kavallaris
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-23

4.  Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.

Authors:  Jianli Zhang; Yue Hong; Jie Shen
Journal:  Tumour Biol       Date:  2015-02-20

Review 5.  Cell survival and metastasis regulation by Akt signaling in colorectal cancer.

Authors:  Ekta Agarwal; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2013-04-18       Impact factor: 4.315

6.  Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.

Authors:  Jie Shen; Yue Hong; Qiong Zhao; Jian-Li Zhang
Journal:  Tumour Biol       Date:  2015-08-13

7.  Salinomycin activates AMP-activated protein kinase-dependent autophagy in cultured osteoblastoma cells: a negative regulator against cell apoptosis.

Authors:  Lun-qing Zhu; Yun-fang Zhen; Ya Zhang; Zhi-xiong Guo; Jin Dai; Xiao-dong Wang
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

8.  Ginsenoside Rg-1 protects retinal pigment epithelium (RPE) cells from cobalt chloride (CoCl2) and hypoxia assaults.

Authors:  Ke-Ran Li; Zhi-Qing Zhang; Jin Yao; Yu-Xia Zhao; Jing Duan; Cong Cao; Qin Jiang
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

9.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.

Authors:  Xing-dong Xu; Lan Yang; Li-yun Zheng; Yan-yan Pan; Zhi-fei Cao; Zhi-qing Zhang; Quan-sheng Zhou; Bo Yang; Cong Cao
Journal:  BMC Cancer       Date:  2014-05-27       Impact factor: 4.430

10.  Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.

Authors:  Falko Lange; Benjamin Franz; Claudia Maletzki; Michael Linnebacher; Maja Hühns; Robert Jaster
Journal:  Biomed Res Int       Date:  2014-09-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.